TITLE

Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis

AUTHOR(S)
Girois, S. B.; Chapuis, F.; Decullier, E.; Revol, B. G. P.
PUB. DATE
February 2006
SOURCE
European Journal of Clinical Microbiology & Infectious Diseases;Feb2006, Vol. 25 Issue 2, p138
SOURCE TYPE
Academic Journal
DOC. TYPE
Correction notice
ABSTRACT
Amphotericin B is the main therapeutic agent for the treatment of invasive fungal infections; however, it is associated with significant toxicities that limit its use. Other systemic antifungal agents have been developed to improve tolerability while maintaining the efficacy profile of conventional amphotericin B. Fifty-four studies involving 9,228 patients were assessed for the frequency of adverse effects of the main systemic antifungal agents. While the results suggest that liposomal amphotericin B is the least nephrotoxic of the lipid formulations (14.6%), that conventional amphotericin B is the most nephrotoxic (33.2%), and that itraconazole is the most hepatotoxic (31.5%), the lack of standard definitions of antifungal-related adverse effects limits the validity of these results. Furthermore, heterogeneous patient pools and differing protocols make it difficult to draw direct comparisons between studies. With the advent of newer classes of systemic antifungal agents, future trials should conform to definitions that are universally applicable and clinically relevant to allow for such comparisons and to enable evidence-based decision-making.
ACCESSION #
19918137

 

Related Articles

  • Antimicóticos de uso sistémico: ¿Con que opciones terapéuticas contamos? G., ANA MARÍA RIVAS; CARDONA-CASTRO, NORA // CES Medicina;2009, Vol. 23 Issue 1, p61 

    The prevalence of invasive fungal infections has increased over the past three decades owing to the increasing numbers of immunocompromised hosts. For many years, amphotericin B and flucytosine were the only available antifungal agents for invasive fungal infections. Fortunately, the antifungal...

  • An Evaluation of Hepatotoxicity and Nephrotoxicity of Liposomal Amphotericin B (L-AMB). Patel, Gourang P.; Crank, Christopher W.; Leikin, Jerrold B. // Journal of Medical Toxicology;Mar2011, Vol. 7 Issue 1, p12 

    Hepatic and renal functions are important considerations when selecting antifungal therapy. This investigation of liposomal amphotericin B (L-AMB) was conducted to determine the incidence and factors associated with the development of hepatotoxicity and nephrotoxicity. A retrospective chart...

  • Systematic review and meta-analysis of the tolerability and hepatotoxicity of antifungals in empirical and definitive therapy for invasive fungal infection. Wang, J. L.; Chang, C. H.; Young-Xu, Y. // Journal of Invasive Fungal Infections;2010, Vol. 4 Issue 4, p152 

    In this meta-analysis, the authors evaluated the hepatotoxicity of antifungal agents in the treatment of invasive fungal infections, and examined whether hepatotoxicity was the cause of treatment discontinuation and study withdrawal. The risk of hepatotoxicity was higher in patients with...

  • High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Lafaurie, M.; Lapalu, J.; Raffoux, E. // Journal of Invasive Fungal Infections;2010, Vol. 4 Issue 4, p150 

    In this study, the authors sought to determine the efficacy of antifungal agents for preventing breakthrough invasive aspergillosis (IA) in a cohort of patients with persistent fever and neutropenia who received empirical antifungal therapy. Caspofungin was the most prescribed antifungal agent,...

  • The new antifungals-- safe and effective. Gallagher, Jason C.; Kauffman, Carol A.; Perfect, John // Patient Care;Jun2005, Vol. 39 Issue 6, p41 

    Discusses the advantages and indications of several antifungal agents. Reasons that the increased incidence of fungal infections shows no sign of decline or leveling of; Alternatives to amphotericin B deoxycholate; Infections caused by fungi, eukaryotes that are more complex organisms than...

  • Empirical Antifungal Therapy in Treating Febrile Neutropenic Patients. Wingard, John R. // Clinical Infectious Diseases;7/15/2004 Supplement 1, Vol. 39, pS38 

    Persistent or recurrent unexplained fever in neutropenic patients receiving antibiotics can be caused by invasive fungal infections, which are often difficult to diagnose. Early trials of empirical antifungal therapy with amphotericin B deoxycholate (AmB) documented reductions in the frequency...

  • Surface Response Modeling to Examine the Combination of Amphotericin B Deoxycholate and 5-Fluorocytosine for Treatment of Invasive Candidiasis. Hope, William W.; Warn, Peter A.; Sharp, Andrew; Reed, Paul; Keevil, Brian; Louie, Arnold; Denning, David W.; Drusano, George L. // Journal of Infectious Diseases;8/15/2005, Vol. 192 Issue 4, p673 

    The strategy of combining antifungal drugs in a treatment regimen may improve the outcome of invasive candidiasis. Using a well-validated pharmaco dynamic murine model of invasive candidiasis, we defined the effect of the combination of amphotericin B deoxycholate (AmB) and 5-fluorocytosine...

  • Combination Antifungal Therapy for Invasive Aspergillosis: Utilizing New Targeting Strategies. Steinbach, William J. // Current Drug Targets - Infectious Disorders;Sep2005, Vol. 5 Issue 3, p203 

    The optimal therapy for invasive aspergillosis (IA) is unknown, and there is little agreement on the exact antifungal management of IA. The previously stagnant landscape of antifungal choices for IA is rapidly changing with newer antifungals and newer targets. While amphotericin B has...

  • Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Girois, S.B.; Chapuis, F.; Decullier, E.; Revol, B.G.P. // European Journal of Clinical Microbiology & Infectious Diseases;Feb2005, Vol. 24 Issue 2, p119 

    Amphotericin B is the main therapeutic agent for the treatment of invasive fungal infections; however, it is associated with significant toxicities that limit its use. Other systemic antifungal agents have been developed to improve tolerability while maintaining the efficacy profile of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics